Amber M. Johnson

ORCID: 0000-0002-6202-6113
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Ovarian cancer diagnosis and treatment
  • RNA Research and Splicing
  • DNA and Nucleic Acid Chemistry
  • Genomics and Rare Diseases
  • Bioinformatics and Genomic Networks
  • Lung Cancer Treatments and Mutations
  • Computational Drug Discovery Methods
  • Genetic factors in colorectal cancer
  • Radiomics and Machine Learning in Medical Imaging
  • Biomedical Text Mining and Ontologies
  • BRCA gene mutations in cancer
  • HER2/EGFR in Cancer Research
  • Supramolecular Chemistry and Complexes
  • Colorectal Cancer Treatments and Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Chemical Synthesis and Analysis
  • Protein Degradation and Inhibitors
  • Advanced Biosensing Techniques and Applications
  • Chemical Reactions and Isotopes
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Genetics, Bioinformatics, and Biomedical Research
  • Fibroblast Growth Factor Research
  • Ethics in Clinical Research

Pfizer (United States)
2021-2025

Cogent Biosciences (United States)
2022-2025

The University of Texas MD Anderson Cancer Center
2015-2024

The University of Texas at Austin
2014-2022

Saint Louis University
2022

Rockefeller University
2020

Florida College
2017

University of Florida
2017

University of California, Riverside
2011-2015

Portland State University
2012

Using scanning tunneling microscopy and spectroscopy, we probe the electronic structures of single layer MoS2 on graphite. The apparent quasiparticle energy gap is measured to be 2.15 ± 0.06 eV at 77 K, albeit a higher second conduction band threshold 0.2 above minimum also observed. Combining it with photoluminescence studies, deduce an exciton binding 0.22 0.1 (or 0.42 if use), value that lower than current theoretical predictions. Consistent predictions, directly observe metallic edge...

10.1021/nl501133c article EN Nano Letters 2014-05-01

By using a comprehensive form of scanning tunneling spectroscopy, we have revealed detailed quasi-particle electronic structures in transition metal dichalcogenides, including the gaps, critical point energy locations, and their origins Brillouin zones. We show that single layer WSe2 surprisingly has an indirect gap with conduction band minimum located at Q-point (instead K), albeit two states are nearly degenerate. further observed rich dichalcogenides as function atomic spin–orbit...

10.1021/acs.nanolett.5b01968 article EN Nano Letters 2015-09-21

An ASCO provisional clinical opinion offers timely direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This addresses the appropriate use tumor genomic testing in patients with metastatic advanced solid tumors.An increasing number therapies are approved treat cancers harboring specific biomarkers. However, there is a lack clarity as when sequencing should be ordered, what type assays performed, and how interpret...

10.1200/jco.21.02767 article EN Journal of Clinical Oncology 2022-02-17

Endohedrally functionalized bis(pyridine) ligands show the ability to self-discriminate when treated with coordinating metals form self-assembled clusters. Self-sorting between components is controlled by substitution on interior of complex. Tuning size internal substituent allows selective heterocluster formation, determined noncovalent and space-filling interactions. This novel method self-sorting discrimination identical geometry donor type.

10.1021/ic2001688 article EN Inorganic Chemistry 2011-04-25

Further advances of targeted cancer therapy require comprehensive in-depth profiling somatic mutations that are present in subpopulations tumor cells a clinical sample. However, it is unclear to what extent such intratumor heterogeneity and whether may affect decision-making. To study this question, we established deep sequencing platform identify potentially actionable DNA alterations samples.We assayed 515 formalin-fixed paraffin-embedded (FFPE) samples matched germline (475 patients) from...

10.1373/clinchem.2014.231100 article EN Clinical Chemistry 2015-01-27

Advances in molecular technologies and targeted therapeutics have accelerated the implementation of precision oncology, resulting improved clinical outcomes selected patients. The use next-generation sequencing assessments immune other biomarkers helps optimize patient treatment selection. In this review, oncology trials including IMPACT, SHIVA, IMPACT2, NCI-MPACT, TAPUR, DRUP, NCI-MATCH studies are summarized, their challenges opportunities discussed. Brief summaries new ComboMATCH,...

10.3390/cancers15071967 article EN Cancers 2023-03-25

Abstract A combination of self‐complementary hydrogen bonding and metal–ligand interactions allows stereocontrol in the self‐assembly prochiral ligand scaffolds. unique, non‐tetrahedral M 4 L 6 structure is observed upon multicomponent 2,7‐diaminofluorenol with 2‐formylpyridine Fe(ClO ) 2 . The stereochemical outcome assembly controlled by between both individual ligands a suitably sized counterion as template. This hydrogen‐bonding‐mediated stereoselective formation nonsymmetric discrete...

10.1002/anie.201405242 article EN Angewandte Chemie International Edition 2014-07-17

A series of tetracationic M2L4 palladium-pyridyl complexes with endohedral amine functionality have been synthesized. The were analyzed by NMR techniques (including Diffusion and 2D NOESY), electrospray ionization (ESI) mass spectrometry, X-ray crystallography. solid state analysis shows a large change in crystal morphology upon introduction the groups, caused deleterious interactions between amines triflate counterions from coordination process. Combination different ligands allows ligand...

10.1021/ic201092s article EN Inorganic Chemistry 2011-09-08

Despite growing therapeutic relevance of ERBB2 amplifications in colorectal cancer (CRC), little is known about ERBB2/ERBB3 mutations. We aimed to characterize these subsets CRC.We performed a retrospective analysis 419 CRC patients from MD Anderson (MDACC) and 619 the Nurses' Health Study (NHS)/Health Professionals Follow-Up (HPFS) with tissue sequencing, clinicopathologic, mutational, consensus molecular subtype (CMS) profiles mutant patients. A third cohort 1623 ctDNA assays characterized...

10.1093/jnci/djy067 article EN JNCI Journal of the National Cancer Institute 2018-03-20

// Genevieve M. Boland 1,2 , Sarina A. Piha-Paul 3 Vivek Subbiah Mark Routbort 4 Shelley Herbrich 5 Keith Baggerly 6 Keyur P. Patel Lauren Brusco Chacha Horombe 7 Aung Naing Siqing Fu David S. Hong Filip Janku Amber Johnson Russell Broaddus 8 Raja Luthra Kenna Shaw John Mendelsohn Gordon B. Mills 7,9 and Funda Meric-Bernstam 2,3,7 1 Division of Surgical Oncology, Department Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA 2 The University Texas MD Anderson...

10.18632/oncotarget.4040 article EN Oncotarget 2015-05-08

Abstract By using silver nanoplatelets with a widely tunable localized surface plasmon resonance (LSPR) and their corresponding local field enhancement, here we show large manipulation of plasmonic enhanced upconversion in NaYF4:Yb 3+ /Er nanocrystals at the single particle level. In particular, that when nanolplatelets is tuned to 656 nm, matching emission wavelength, an enhancement factor ~5 obtained. However, 980 nanocrystal absorption achieve ~22 folds. The precise geometric arrangement...

10.1038/srep10196 article EN cc-by Scientific Reports 2015-05-15

High-throughput genomic and molecular profiling of tumors is emerging as an important clinical approach. Molecular increasingly being used to guide cancer patient care, especially in advanced incurable cancers. However, navigating the scientific literature make evidence-based decisions based on results overwhelming for many oncology clinicians researchers. The Personalized Cancer Therapy website (www.personalizedcancertherapy.org) was created provide online resource researchers facilitate...

10.1158/0008-5472.can-17-0341 article EN Cancer Research 2017-10-31

Development of a scalable route for the synthesis nirmatrelvir, novel SARS-CoV-2 3C-like protease inhibitor discovered in 2020 by Pfizer scientists, was initiated shortly thereafter to supply material first clinical studies. This optimized commercial manufacture nirmatrelvir high yield and acceptable quality with consideration efficiency sustainability. Herein, we report evolution final steps (3–5) used synthesize (steps 3–5), from initial regulatory lot design implementation process.

10.1021/acs.oprd.3c00250 article EN Organic Process Research & Development 2023-11-17
Coming Soon ...